Xanodyne Pharmaceuticals, Inc. has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zipsor, its candidate for the treatment of patients with mild to moderate acute pain. Gregory Flexter, president and CEO of the Newport-based company, said Xanodyne has been informed that no additional clinical trials have been requested and said the company will work closely with the FDA to provide a complete response.
Add Comment